Comparison
Ipamorelin vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
170851-70-4
2179963-22-7
Molecular weight
711.86 g/mol
4727 g/mol
Half-life
2 h
168 h
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
2
of which in humans
3
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2